Stock Track | Novavax Soars 5.19% on Narrower Q4 Loss, Stronger Revenue; Shifts Focus Beyond COVID Vaccine

Stock Track

Feb 27, 2025

Shares of Novavax (NVAX) soared 5.19% in pre-market trading on Thursday, following the company's better-than-expected fourth quarter results and outlook as it transitions away from direct commercialization of its COVID-19 vaccine Nuvaxovid.

For the quarter, Novavax reported an adjusted loss per share of $0.51, narrower than the $1.44 loss a year ago and in line with analysts' estimates. Revenue came in at $88.3 million, beating consensus forecasts of $84.4 million. Sales of the COVID vaccine totaled $49.8 million, down 80% year-over-year as the company ramps down its commercial operations.

Novavax has signed a $1.2 billion licensing deal with Sanofi to hand over rights to sell Nuvaxovid in several markets including the U.S. and Europe starting with the 2025-2026 vaccination season. For 2025, the company expects adjusted licensing, royalties and other revenue to range between $300 million and $350 million, but did not provide forecasts for royalties or milestone payments from Sanofi as it transitions the commercial lead.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1101729758"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101729758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101729758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101729758","market":"us","top_or_hot":-1,"title":"Stock Track | Novavax Soars 5.19% on Narrower Q4 Loss, Stronger Revenue; Shifts Focus Beyond COVID Vaccine","media":"Stock Track","content":"<p>Shares of Novavax (NVAX) soared 5.19% in pre-market trading on Thursday, following the company's better-than-expected fourth quarter results and outlook as it transitions away from direct commercialization of its COVID-19 vaccine Nuvaxovid.</p>\n\n<p>For the quarter, Novavax reported an adjusted loss per share of $0.51, narrower than the $1.44 loss a year ago and in line with analysts' estimates. Revenue came in at $88.3 million, beating consensus forecasts of $84.4 million. Sales of the COVID vaccine totaled $49.8 million, down 80% year-over-year as the company ramps down its commercial operations.</p>\n\n<p>Novavax has signed a $1.2 billion licensing deal with Sanofi to hand over rights to sell Nuvaxovid in several markets including the U.S. and Europe starting with the 2025-2026 vaccination season. For 2025, the company expects adjusted licensing, royalties and other revenue to range between $300 million and $350 million, but did not provide forecasts for royalties or milestone payments from Sanofi as it transitions the commercial lead.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novavax Soars 5.19% on Narrower Q4 Loss, Stronger Revenue; Shifts Focus Beyond COVID Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novavax Soars 5.19% on Narrower Q4 Loss, Stronger Revenue; Shifts Focus Beyond COVID Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-27 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Novavax (NVAX) soared 5.19% in pre-market trading on Thursday, following the company's better-than-expected fourth quarter results and outlook as it transitions away from direct commercialization of its COVID-19 vaccine Nuvaxovid.</p>\n\n<p>For the quarter, Novavax reported an adjusted loss per share of $0.51, narrower than the $1.44 loss a year ago and in line with analysts' estimates. Revenue came in at $88.3 million, beating consensus forecasts of $84.4 million. Sales of the COVID vaccine totaled $49.8 million, down 80% year-over-year as the company ramps down its commercial operations.</p>\n\n<p>Novavax has signed a $1.2 billion licensing deal with Sanofi to hand over rights to sell Nuvaxovid in several markets including the U.S. and Europe starting with the 2025-2026 vaccination season. For 2025, the company expects adjusted licensing, royalties and other revenue to range between $300 million and $350 million, but did not provide forecasts for royalties or milestone payments from Sanofi as it transitions the commercial lead.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"","article_id":"1101729758","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101729758","pubTimestamp":1740667435,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Novavax  soared 5.19% in pre-market trading on Thursday, following the company's better-than-expected fourth quarter results and outlook as it transitions away from direct commercialization of its COVID-19 vaccine Nuvaxovid.For the quarter, Novavax reported an adjusted loss per share of $0.51, narrower than the $1.44 loss a year ago and in line with analysts' estimates. Revenue came in at $88.3 million, beating consensus forecasts of $84.4 million. Sales of the COVID vaccine totaled $4","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"股票赛道Novavax因第四季度亏损收窄、收入强劲而飙升5.19%；将焦点转移到新冠疫苗之外","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1},"content_text":"Shares of Novavax (NVAX) soared 5.19% in pre-market trading on Thursday, following the company's better-than-expected fourth quarter results and outlook as it transitions away from direct commercialization of its COVID-19 vaccine Nuvaxovid.\nFor the quarter, Novavax reported an adjusted loss per share of $0.51, narrower than the $1.44 loss a year ago and in line with analysts' estimates. Revenue came in at $88.3 million, beating consensus forecasts of $84.4 million. Sales of the COVID vaccine totaled $49.8 million, down 80% year-over-year as the company ramps down its commercial operations.\nNovavax has signed a $1.2 billion licensing deal with Sanofi to hand over rights to sell Nuvaxovid in several markets including the U.S. and Europe starting with the 2025-2026 vaccination season. For 2025, the company expects adjusted licensing, royalties and other revenue to range between $300 million and $350 million, but did not provide forecasts for royalties or milestone payments from Sanofi as it transitions the commercial lead.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}